Proteasome inhibitors in multiple myeloma: 10 years la

Blood

120, 947-959

DOI: 10.1182/blood-2012-04-403733

Citation Report

#	Article	IF	Citations
1	AACR Cancer Progress Report 2012. Clinical Cancer Research, 2012, 18, S1-S100.	3.2	28
2	HDAC Inhibitor Modulation of Proteotoxicity as a Therapeutic Approach in Cancer. Advances in Cancer Research, 2012, 116, 131-163.	1.9	31
3	Activity Enhancement of the Synthetic Syrbactin Proteasome Inhibitor Hybrid and Biological Evaluation in Tumor Cells. Biochemistry, 2012, 51, 6880-6888.	1.2	27
4	Drug Allergy. , 2013, , .		31
5	Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review. International Journal of Hematology, 2013, 97, 800-803.	0.7	27
6	Current approaches for the treatment of multiple myeloma. International Journal of Hematology, 2013, 97, 333-344.	0.7	25
7	Georgia on my mind: multiple myeloma highlights at ASH 2012. Memo - Magazine of European Medical Oncology, 2013, 6, 189-192.	0.3	1
8	Topical evening primrose oil for reduction of bortezomib-induced skin reactions. Annals of Hematology, 2013, 92, 995-996.	0.8	3
9	Subcutaneous Bortezomib. Drugs, 2013, 73, 45-54.	4.9	15
10	Proteasome Inhibitor Therapy for WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 235-237.	0.2	6
11	Macrophages in multiple myeloma: emerging concepts and therapeutic implications. Leukemia and Lymphoma, 2013, 54, 2112-2121.	0.6	47
12	High incidence and severity of injection site reactions in the first cycle compared with subsequent cycles of subcutaneous bortezomib. International Journal of Hematology, 2013, 98, 694-701.	0.7	5
13	Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication. Retrovirology, 2013, 10, 120.	0.9	26
14	Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma. Cancer Cell, 2013, 24, 275-277.	7.7	30
16	To Market, To Marketâ€"2012. Annual Reports in Medicinal Chemistry, 2013, 48, 471-546.	0.5	14
17	Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma, 2013, 54, 1996-2002.	0.6	41
18	SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma. Nature Cell Biology, 2013, 15, 72-81.	4.6	76
19	Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials. Seminars in Oncology, 2013, 40, 634-651.	0.8	38

#	Article	IF	Citations
20	Initial Treatment of Transplant Candidates With Multiple Myeloma. Seminars in Oncology, 2013, 40, 585-591.	0.8	7
21	Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells inÂvitro but have additive anti-myeloma activity inÂvivo. Experimental Hematology, 2013, 41, 1038-1049.	0.2	26
22	Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen. European Journal of Haematology, 2013, 90, 157-161.	1.1	17
23	Profiling drug-induced cell death pathways in the zebrafish lateral line. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 393-408.	2.2	73
24	Proteasome inhibitors in acute leukemia. Expert Review of Anticancer Therapy, 2013, 13, 327-337.	1.1	38
25	Proteasome inhibitor <scp>MG</scp>â€132 induces <scp>MCPIP</scp>1 expression. FEBS Journal, 2013, 280, 2665-2674.	2.2	26
26	Emerging pathways as individualized therapeutic target of multiple myeloma. Expert Opinion on Biological Therapy, 2013, 13, S95-S109.	1.4	37
27	Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors. Experimental Hematology and Oncology, 2013, 2, 2.	2.0	17
28	Understanding, recognizing, and managing toxicities of targeted anticancer therapies. Ca-A Cancer Journal for Clinicians, 2013, 63, 249-279.	157.7	274
29	Takeda's Oncology Discovery Strategy. Japanese Journal of Clinical Oncology, 2013, 43, 357-361.	0.6	2
30	Drugs Used for Chemotherapy. , 2013, , 399-418.		1
31	Bortezomib and SAHA Synergistically Induce ROS-Driven Caspase-Dependent Apoptosis of Nasopharyngeal Carcinoma and Block Replication of Epsteinâ€"Barr Virus. Molecular Cancer Therapeutics, 2013, 12, 747-758.	1.9	70
32	Degradation of NF-ÎºB, p53 and other regulatory redox-sensitive proteins by thiol-conjugating and -nitrosylating drugs in human tumor cells. Carcinogenesis, 2013, 34, 990-1000.	1.3	30
33	The Novel Orally Active Proteasome Inhibitor K-7174 Exerts Anti-myeloma Activity in Vitro and in Vivo by Down-regulating the Expression of Class I Histone Deacetylases. Journal of Biological Chemistry, 2013, 288, 25593-25602.	1.6	23
34	Panobinostat in lymphoid and myeloid malignancies. Expert Opinion on Investigational Drugs, 2013, 22, 1211-1223.	1.9	39
35	Second autologous transplant as salvage therapy in multiple myeloma. British Journal of Haematology, 2013, 163, 565-572.	1.2	37
36	Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood, 2013, 121, 5055-5063.	0.6	171
37	Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells. International Journal of Oncology, 2013, 42, 1541-1550.	1.4	87

#	Article	IF	Citations
39	Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. Haematologica, 2013, 98, 1896-1904.	1.7	53
40	Strategies for the Treatment of Multiple Myeloma in 2013: Moving Toward the Cure. , 0, , .		0
41	Non-Covalent Proteasome Inhibitors. Current Pharmaceutical Design, 2013, 19, 4115-4130.	0.9	18
42	Homopiperazine Derivatives as a Novel Class of Proteasome Inhibitors with a Unique Mode of Proteasome Binding. PLoS ONE, 2013, 8, e60649.	1.1	14
43	Activation of Coagulation by Lenalidomide-Based Regimens for the Treatment of Multiple Myeloma. PLoS ONE, 2013, 8, e64369.	1.1	9
44	Proteasome Inhibitors Block DNA Repair and Radiosensitize Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e73710.	1.1	47
45	1,2,4-Oxadiazoles Identified by Virtual Screening and their Non-Covalent Inhibition of the Human 20S Proteasome. Current Medicinal Chemistry, 2013, 20, 2351-2362.	1.2	25
46	Proteasomes and Proteasomal Gene Polymorphism in Association with Inflammation and Various Diseases. Medicina (Lithuania), 2013, 49, 33.	0.8	8
47	Eosinophils and Megakaryocytes Support the Early Growth of Murine MOPC315 Myeloma Cells in Their Bone Marrow Niches. PLoS ONE, 2014, 9, e109018.	1.1	27
48	Utilization of Translational Bioinformatics to Identify Novel Biomarkers of Bortezomib Resistance in Multiple Myeloma. Journal of Cancer, 2014, 5, 720-727.	1.2	20
49	Recent Developments in Cancer Treatment: A Review. Pharmaceutical Regulatory Affairs: Open Access, 2014, 03, .	0.2	0
50	Efficacy of Subcutaneous Bortezomib in the Management of Patients with Multiple Myeloma or Relapsed Mantle Cell Lymphoma. Clinical Medicine Insights Therapeutics, 2014, 6, CMT.S9308.	0.4	1
51	Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials. Future Oncology, 2014, 10, 1795-1807.	1.1	101
52	The emerging role of carfilzomib combination therapy in the management of multiple myeloma. Expert Review of Hematology, 2014, 7, 265-290.	1.0	20
53	Immunotherapeutic approaches to treat multiple myeloma. Human Vaccines and Immunotherapeutics, 2014, 10, 896-910.	1.4	7
54	Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients. Blood Cancer Journal, 2014, 4, e212-e212.	2.8	7
55	Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood, 2014, 124, 1038-1046.	0.6	192
56	Short-course bortezomib-based retreatment for patients with multiple myeloma who had received bortezomib-thalidomide-dexamethasone (VTD) as an initial therapy: A single-center case series. Experimental and Therapeutic Medicine, 2014, 7, 977-981.	0.8	3

#	Article	IF	Citations
57	The Positive Effects of One-Hour Intravenous Administration of Bortezomib on Peripheral Neuropathy in Multiple Myeloma Patients. BioMed Research International, 2014, 2014, 1-6.	0.9	3
58	Establishment of Cell Lines from Both Myeloma Bone Marrow and Plasmacytoma: SNU_MM1393_BM and SNU_MM1393_SC from a Single Patient. BioMed Research International, 2014, 2014, 1-8.	0.9	4
59	Expression Profile of the Schistosoma japonicum Degradome Reveals Differential Protease Expression Patterns and Potential Anti-schistosomal Intervention Targets. PLoS Computational Biology, 2014, 10, e1003856.	1.5	26
60	Quantitative analysis of a ubiquitinâ€dependent substrate using capillary electrophoresis with dual laserâ€induced fluorescence. Electrophoresis, 2014, 35, 2978-2985.	1.3	0
61	Calcineurin inhibitors suppress the high-temperature stress sensitivity of the yeast ubiquitin ligase Rsp5 mutant: a new method of screening for calcineurin inhibitors. FEMS Yeast Research, 2014, 14, 567-574.	1.1	8
63	Molecular Pathways: Translational Potential of Deubiquitinases as Drug Targets. Clinical Cancer Research, 2014, 20, 3908-3914.	3.2	53
64	Profile of elotuzumab and its potential in the treatment of multiple myeloma. Blood and Lymphatic Cancer: Targets and Therapy, 2014, 2014, 15.	1.2	26
65	The complexity of recognition of ubiquitinated substrates by the 26S proteasome. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 86-96.	1.9	130
66	Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effectiveâ€"A report by Polish Myeloma Study Group. Leukemia Research, 2014, 38, 788-794.	0.4	4
67	Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors. Bone, 2014, 61, 39-43.	1.4	11
68	Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma. Oncogene, 2014, 33, 1877-1889.	2.6	29
69	Total Synthesis of Syringolinâ€…A and Improvement of Its Biological Activity. Angewandte Chemie - International Edition, 2014, 53, 4836-4839.	7.2	21
70	Peptideâ€Based Proteasome Inhibitors in Anticancer Drug Design. Medicinal Research Reviews, 2014, 34, 1001-1069.	5.0	46
71	Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism. International Journal of Cancer, 2014, 135, 2950-2961.	2.3	49
72	Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia, 2014, 28, 993-1000.	3.3	92
73	Mechanisms and consequences of constitutive NF-ÎºB activation in B-cell lymphoid malignancies. Oncogene, 2014, 33, 5655-5665.	2.6	112
74	Therapeutic Benefit of Bortezomib on Acute Graft-versus-Host Disease Is Tissue Specific and Is Associated with Interleukin-6 Levels. Biology of Blood and Marrow Transplantation, 2014, 20, 1899-1904.	2.0	24
75	Antimyeloma activity of NK012, a micelleâ€forming macromolecular prodrug of SNâ€38, in an orthotopic model. International Journal of Cancer, 2014, 134, 218-223.	2.3	12

#	Article	IF	Citations
76	An iron-regulated and glycosylation-dependent proteasomal degradation pathway for the plasma membrane metal transporter ZIP14. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 9175-9180.	3.3	54
77	Degradation of a connexin40 mutant linked to atrial fibrillation is accelerated. Journal of Molecular and Cellular Cardiology, 2014, 74, 330-339.	0.9	24
79	Adverse Events to Nontargeted and Targeted Chemotherapeutic Agents. Immunology and Allergy Clinics of North America, 2014, 34, 565-596.	0.7	30
80	Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia. Leukemia, 2014, 28, 1216-1226.	3.3	55
81	European Perspective on Multiple Myeloma Treatment Strategies in 2014. Oncologist, 2014, 19, 829-844.	1.9	90
82	Initial treatment of transplant-eligible patients in multiple myeloma. Expert Review of Hematology, 2014, 7, 43-53.	1.0	14
83	A spatial simulation approach to account for protein structure when identifying non-random somatic mutations. BMC Bioinformatics, 2014, 15, 231.	1.2	21
84	Targeting the Ubiquitin-Proteasome System in Heart Disease: The Basis for New Therapeutic Strategies. Antioxidants and Redox Signaling, 2014, 21, 2322-2343.	2.5	55
85	MCPIP1 contributes to the toxicity of proteasome inhibitor MG-132 in HeLa cells by the inhibition of NF-ÎºB. Molecular and Cellular Biochemistry, 2014, 395, 253-263.	1.4	13
86	Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells. Cancer Chemotherapy and Pharmacology, 2014, 73, 1263-1271.	1.1	10
87	Proapoptotic effects of the novel proteasome inhibitor b-AP15 on multiple myeloma cells and natural killer cells. Experimental Hematology, 2014, 42, 172-182.	0.2	21
88	An analysis of the safety profile of proteasome inhibitors for treating various cancers. Expert Opinion on Drug Safety, 2014, 13, 1043-1054.	1.0	17
89	Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells. International Journal of Hematology, 2014, 99, 726-736.	0.7	12
90	HO-1 up-regulation: A key point in high-risk neuroblastoma resistance to bortezomib. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 613-622.	1.8	46
91	Linking the activity of bortezomib in multiple myeloma and autoimmune diseases. Critical Reviews in Oncology/Hematology, 2014, 92, 61-70.	2.0	20
92	Development of inhibitors in the ubiquitination cascade. FEBS Letters, 2014, 588, 356-367.	1.3	67
93	Neurotoxicity induced by antineoplastic proteasome inhibitors. NeuroToxicology, 2014, 43, 28-35.	1.4	43
94	Curcusone D, a novel ubiquitinâ€"proteasome pathway inhibitor via ROS-induced DUB inhibition, is synergistic with bortezomib against multiple myeloma cell growth. Biochimica Et Biophysica Acta - General Subjects, 2014, 1840, 2004-2013.	1.1	22

#	Article	IF	Citations
95	Meta-Analysis of the Efficacy and Safety of Bortezomib Re-Treatment in Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 380-388.	0.2	38
96	The ubiquitin proteasome system â€" Implications for cell cycle control and the targeted treatment of cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 150-162.	1.9	214
97	DNA damage emergency: cellular garbage disposal to the rescue?. Oncogene, 2014, 33, 805-813.	2.6	17
98	Morphology and immunophenotyping issues in the integrated diagnosis of hematologic disorders of elderly patients. Haematologica, 2014, 99, 951-953.	1.7	0
99	Treatment of chronic graft-versus-host disease with bortezomib. Blood, 2014, 124, 1677-1688.	0.6	72
100	First do no harm: infectious deaths in pediatric ALL. Blood, 2014, 124, 987-989.	0.6	0
101	Oral therapy for multiple myeloma: ixazomib arriving soon. Blood, 2014, 124, 986-987.	0.6	14
103	Proteasomal inhibition sensitizes cervical cancer cells to mitomycin C-induced bystander effect: the role of tumor microenvironment. Cell Death and Disease, 2015, 6, e1934-e1934.	2.7	33
104	How I treat fragile myeloma patients. Blood, 2015, 126, 2179-2185.	0.6	63
105	Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis. Lupus Science and Medicine, 2015, 2, e000121.	1.1	8
106	DziesiÄ™ciolecie Polskiej Grupy Szpiczakowej â€" historia i osiÄ…gniÄ™cia. Acta Haematologica Polonica, 2015, 46, 212-223.	0.1	0
107	A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research, 2015, 21, 2730-2736.	3.2	41
108	Emerging Therapies in Multiple Myeloma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 315-321.	0.6	26
109	KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism. PLoS ONE, 2015, 10, e0144825.	1.1	16
110	Heat Shock Protein 90 and the Proteasome. , 2015, , 779-788.e3.		1
111	Regulation of c-Myc protein stability by proteasome activator REGÎ³. Cell Death and Differentiation, 2015, 22, 1000-1011.	5.0	39
112	When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response. Molecular Cancer Research, 2015, 13, 1163-1173.	1.5	43
113	Well plate-based perfusion culture device for tissue and tumor microenvironment replication. Lab on A Chip, 2015, 15, 2854-2863.	3.1	15

#	Article	IF	Citations
114	An Acceptable Incidence of Infusion Site Reactions after Subcutaneous Bortezomib Administration in the Upper Arm in Japanese Patients with Multiple Myeloma. Acta Haematologica, 2015, 133, 29-30.	0.7	2
115	Therapeutic Landscape of Carfilzomib and Other Modulators of the Ubiquitin-Proteasome Pathway. Journal of Clinical Oncology, 2015, 33, 782-785.	0.8	15
116	Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma. Pharmaceuticals, 2015, 8, 1-20.	1.7	76
117	Cryo-EM reveals the conformation of a substrate analogue in the human 20S proteasome core. Nature Communications, 2015, 6, 7573.	5.8	40
118	Inhibition of the 26S proteasome by peptide mimics of the coiled-coil region of its ATPase subunits. Biochemical and Biophysical Research Communications, 2015, 468, 143-150.	1.0	7
119	Relevance of the thyroid hormonesâ€"Î±vÎ²3 pathway in primary myeloma bone marrow cells and to bortezomib action. Leukemia and Lymphoma, 2015, 56, 1107-1114.	0.6	26
120	Treatment-related symptom management in patients with multiple myeloma: a review. Supportive Care in Cancer, 2015, 23, 1431-1445.	1.0	34
121	The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2015, 74, 1474-1478.	0.5	298
122	Trial Watch: Proteasomal inhibitors for anticancer therapy. Molecular and Cellular Oncology, 2015, 2, e974463.	0.3	18
123	Other Nonbiological Approaches to Targeted Cancer Chemotherapy. , 2015, , 493-560.		1
124	Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma. Expert Review of Hematology, 2015, 8, 481-491.	1.0	29
126	PU-H71: An improvement on nature's solutions to oncogenic Hsp90 addiction. Pharmacological Research, 2015, 99, 202-216.	3.1	32
127	Switching from body surface areaâ€based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis. British Journal of Clinical Pharmacology, 2015, 79, 789-800.	1.1	50
128	Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma. Journal of Controlled Release, 2015, 211, 44-52.	4.8	49
129	Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment. Experimental Hematology, 2015, 43, 168-176.e2.	0.2	13
130	Mixed galactolipid anomers accentuate apoptosis of multiple myeloma cells by inducing DNA damage. Carbohydrate Research, 2015, 408, 114-118.	1.1	8
131	Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. Investigational New Drugs, 2015, 33, 652-663.	1.2	35
132	Proteasome inhibitors as experimental therapeutics of autoimmune diseases. Arthritis Research and Therapy, 2015, 17, 17.	1.6	101

#	Article	IF	Citations
133	Proteasome inhibitors. Biochemical Pharmacology, 2015, 96, 1-9.	2.0	144
134	CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon. Clinical Cancer Research, 2015, 21, 2660-2662.	3.2	40
135	The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. Future Oncology, 2015, 11, 1153-1168.	1.1	25
136	Ricolinostat (‹scp›ACY‹/scp›â€•1215) induced inhibition of aggresome formation accelerates carfilzomibâ€•induced multiple myeloma cell death. British Journal of Haematology, 2015, 169, 423-434.	1.2	89
137	The novel Î²2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. Cancer Chemotherapy and Pharmacology, 2015, 76, 383-396.	1.1	13
138	Transcriptional repression by the HDAC4â€“RelBâ€“p52 complex regulates multiple myeloma survival and growth. Nature Communications, 2015, 6, 8428.	5.8	53
139	Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Haematologica, 2015, 100, 964-969.	1.7	62
140	Regulation of Proteasomal Degradation by Modulating Proteasomal Initiation Regions. ACS Chemical Biology, 2015, 10, 2537-2543.	1.6	13
141	The Amyloidoses. , 2015, , 279-307.		0
142	Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer Journal, 2015, 5, e338-e338.	2.8	68
143	Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma. Journal of Clinical Oncology, 2015, 33, 732-739.	0.8	88
144	Current treatment landscape for relapsed and/or refractory multiple myeloma. Nature Reviews Clinical Oncology, 2015, 12, 42-54.	12.5	175
145	Recent advances and future directions in targeting the secretory apparatus in multiple myeloma. British Journal of Haematology, 2015, 168, 14-25.	1.2	37
146	A review of the evidence for occupational exposure risks to novel anticancer agents â€“ A focus on monoclonal antibodies. Journal of Oncology Pharmacy Practice, 2016, 22, 121-134.	0.5	22
147	Congenital Immunodeficiency Diseases. , 2016, , 45-81.		0
148	Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. Oncotarget, 2016, 7, 77543-77557.	0.8	62
149	Zoledronic acid overcomes adriamycin resistance in acute myeloid leukemia cells by promoting apoptosis. Molecular Medicine Reports, 2016, 14, 5660-5666.	1.1	2
150	APEH Inhibition Affects Osteosarcoma Cell Viability via Downregulation of the Proteasome. International Journal of Molecular Sciences, 2016, 17, 1614.	1.8	17

#	Article	IF	Citations
151	Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer, 2016, 122, 2050-2056.	2.0	40
152	Bortezomib-induced pro-inflammatory macrophages as a potential factor limiting anti-tumour efficacy. Journal of Pathology, 2016, 239, 262-273.	2.1	24
153	The role of the proteasome in AML. Blood Cancer Journal, 2016, 6, e503-e503.	2.8	43
154	Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood, 2016, 128, 2415-2422.	0.6	51
155	Targeting CK2-driven non-oncogene addiction in B-cell tumors. Oncogene, 2016, 35, 6045-6052.	2.6	24
156	Noncanonical NF-ÎºB Signaling in Health and Disease. Trends in Molecular Medicine, 2016, 22, 414-429.	3.5	237
157	Mangiferin induces apoptosis in multiple myeloma cell lines by suppressing the activation of nuclear factor kappa B-inducing kinase. Chemico-Biological Interactions, 2016, 251, 26-33.	1.7	29
158	Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini. Blood Cancer Journal, 2016, 6, e411-e411.	2.8	20
159	Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell, 2016, 29, 639-652.	7.7	85
160	Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism. Leukemia, 2016, 30, 2198-2207.	3.3	117
161	Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib. Medical Oncology, 2016, 33, 53.	1.2	21
162	Molecular mechanisms for vascular complications of targeted cancer therapies. Clinical Science, 2016, 130, 1763-1779.	1.8	18
163	Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia, 2016, 30, 2169-2178.	3.3	28
164	Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy. Journal of Hematology and Oncology, 2016, 9, 82.	6.9	22
165	NF-ÎºB dysregulation in multiple myeloma. Seminars in Cancer Biology, 2016, 39, 68-76.	4.3	43
166	Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2141-2158.	1.2	17
167	Paraproteinâ€"Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 2273-2279.	2.2	43
168	Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells. Hormones and Cancer, 2016, 7, 345-355.	4.9	12

#	Article	IF	Citations
169	Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1. Cancer Immunology Research, 2016, 4, 779-788.	1.6	80
170	Integration of Novel Agents into the Care of Patients with Multiple Myeloma. Clinical Cancer Research, 2016, 22, 5443-5452.	3.2	36
171	Targeted inhibition of the COP9 signalosome for treatment of cancer. Nature Communications, 2016, 7, 13166.	5.8	131
172	Heat Shock Protein 90 Facilitates Latent HIV Reactivation through Maintaining the Function of Positive Transcriptional Elongation Factor b (p-TEFb) under Proteasome Inhibition. Journal of Biological Chemistry, 2016, 291, 26177-26187.	1.6	25
173	Carfilzomib for treating myeloma. Expert Opinion on Orphan Drugs, 2016, 4, 989-999.	0.5	2
174	Novel immunotherapeutic strategies to target alloantibody-producing B and plasma cells in transplantation. Current Opinion in Organ Transplantation, 2016, 21, 419-426.	0.8	10
175	Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica, 2016, 101, 346-355.	1.7	44
176	Oral proteasome inhibitor with strong preclinical efficacy in myeloma models. BMC Cancer, 2016, 16, 247.	1.1	8
177	Leveraging protein quaternary structure to identify oncogenic driver mutations. BMC Bioinformatics, 2016, 17, 137.	1.2	8
178	New MAPS for misfolded proteins. Nature Cell Biology, 2016, 18, 724-726.	4.6	10
179	Bortezomib for the treatment of multiple myeloma. The Cochrane Library, 2016, 2016, CD010816.	1.5	80
180	Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells. Immunopharmacology and Immunotoxicology, 2016, 38, 87-97.	1.1	13
181	Oral ixazomib maintenance therapy in multiple myeloma. Expert Review of Anticancer Therapy, 2016, 16, 21-32.	1.1	6
182	Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma. Cancer Research, 2016, 76, 3319-3331.	0.4	34
183	HIV-associated Hematological Malignancies. , 2016, , .		4
184	Primary failure of bortezomib in newly diagnosed multiple myeloma â€“ understanding the magnitude, predictors, and significance. Leukemia and Lymphoma, 2016, 57, 1382-1388.	0.6	10
185	Impairment of stress granule assembly via inhibition of the eIF2alpha phosphorylation sensitizes glioma cells to chemotherapeutic agents. Journal of Neuro-Oncology, 2016, 127, 253-260.	1.4	46
186	Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors. Leukemia, 2016, 30, 1094-1102.	3.3	64

#	Article	IF	Citations
187	Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma. BMC Cancer, 2017, 17, 40.	1.1	79
188	Targeting proteasomes in infectious organisms to combat disease. FEBS Journal, 2017, 284, 1503-1517.	2.2	40
189	Proteasome inhibitor MG132 induces thyroid cancer cell apoptosis by modulating the activity of transcription factor FOXO3a. Endocrine, 2017, 56, 98-108.	1.1	18
190	Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies. Current Hematologic Malignancy Reports, 2017, 12, 257-267.	1.2	2
191	The Emerging Role of Non-traditional Ubiquitination in Oncogenic Pathways. Journal of Biological Chemistry, 2017, 292, 3543-3551.	1.6	41
192	Discovery of an Inhibitor of the Proteasome Subunit Rpn11. Journal of Medicinal Chemistry, 2017, 60, 1343-1361.	2.9	61
193	Multifunctional Telodendrimer Nanocarriers Restore Synergy of Bortezomib and Doxorubicin in Ovarian Cancer Treatment. Cancer Research, 2017, 77, 3293-3305.	0.4	40
194	PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4. Oncogene, 2017, 36, 4481-4497.	2.6	22
195	MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway. Cell Death and Disease, 2017, 8, e2776-e2776.	2.7	43
196	A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. British Journal of Haematology, 2017, 178, 547-560.	1.2	48
197	Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma. Blood Cancer Journal, 2017, 7, e569-e569.	2.8	8
198	High-resolution cryo-EM proteasome structures in drug development. Acta Crystallographica Section D: Structural Biology, 2017, 73, 522-533.	1.1	10
199	A Mathematical Model of Cell Cycle Dysregulation Due to Human Papillomavirus Infection. Bulletin of Mathematical Biology, 2017, 79, 1564-1585.	0.9	7
200	Endothelinâ€1 receptor blockade as new possible therapeutic approach in multiple myeloma. British Journal of Haematology, 2017, 178, 781-793.	1.2	21
201	The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib. Acta Clinica Belgica, 2017, 72, 391-398.	0.5	19
202	Therapy for Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 2017, 92, 578-598.	1.4	115
203	Long-term control of extensive refractory chronic graft versus host disease in a multiple myeloma relapsing after allogeneic transplant. A case report. Leukemia and Lymphoma, 2017, 58, 2770-2771.	0.6	1
204	WaldenstrÃ¶m Macroglobulinemia: Review of Pathogenesis and Management. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 252-262.	0.2	38

#	Article	IF	Citations
205	Evaluation of pretreatment red cell distribution width in patients with multiple myeloma. Cancer Biomarkers, 2017, 20, 267-272.	0.8	18
206	CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma. Molecular Cancer Therapeutics, 2017, 16, 2862-2870.	1.9	54
207	Can we improve the conditioning regimen before autologous stem cell transplantation in multiple myeloma?. Expert Opinion on Orphan Drugs, 2017, 5, 875-887.	0.5	3
208	Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study. Annals of Hematology, 2017, 96, 1857-1866.	0.8	17
209	The novel autophagy inhibitor elaiophylin exerts antitumor activity against multiple myeloma with mutant TP53 in part through endoplasmic reticulum stress-induced apoptosis. Cancer Biology and Therapy, 2017, 18, 584-595.	1.5	30
210	The immunoproteasome: An old player with a novel and emerging role in alloimmunity. American Journal of Transplantation, 2017, 17, 3033-3039.	2.6	36
211	ATP-competitive, marine derived natural products that target the DEAD box helicase, eIF4A. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4082-4085.	1.0	22
212	The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug Target. ACS Central Science, 2017, 3, 830-838.	5.3	103
213	Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm. Haematologica, 2017, 102, 1861-1868.	1.7	38
214	Small-Molecule Modulation of Protein Homeostasis. Chemical Reviews, 2017, 117, 11269-11301.	23.0	221
215	Jagged1-induced Notch activation contributes to the acquisition of bortezomib resistance in myeloma cells. Blood Cancer Journal, 2017, 7, 650.	2.8	25
216	An overview of the role of carfilzomib in the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy, 2017, 18, 1883-1897.	0.9	23
217	Proteasome inhibition suppresses Th17 cell generation and ameliorates autoimmune development in experimental SjÃ¶grenâ€™s syndrome. Cellular and Molecular Immunology, 2017, 14, 924-934.	4.8	45
218	Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma. Translational Oncology, 2017, 10, 632-640.	1.7	26
219	Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma. Targeted Oncology, 2017, 12, 535-542.	1.7	16
220	A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma. Blood Cancer Journal, 2017, 7, e581-e581.	2.8	37
221	Naphthoquinone amino acid derivatives, synthesis and biological activity as proteasome inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 865-877.	2.5	10
222	Proteasomal Dysfunction Induced By Diclofenac Engenders Apoptosis Through Mitochondrial Pathway. Journal of Cellular Biochemistry, 2017, 118, 1014-1027.	1.2	13

#	Article	IF	Citations
224	Second Generation Proteasome Inhibitors in Multiple Myeloma. Anti-Cancer Agents in Medicinal Chemistry, 2017, 17, 920-926.	0.9	11
225	Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactions. Oncology Letters, 2017, 14, 3185-3192.	0.8	6
226	Reduced Response of IRE1Î±/Xbp-1 Signaling Pathway to Bortezomib Contributes to Drug Resistance in Multiple Myeloma Cells. Tumori, 2017, 103, 261-267.	0.6	8
227	Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics. Pharmaceuticals, 2017, 10, 40.	1.7	33
228	Therapeutic Strategies against Epstein-Barr Virus-Associated Cancers Using Proteasome Inhibitors. Viruses, 2017, 9, 352.	1.5	16
229	High Cut-Off Hemodialysis for Myeloma Cast Nephropathy â€“ Do We Finally Have An Answer?. Journal of Onco-Nephrology, 2017, 1, 67-70.	0.3	7
230	Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic Leukemia in an Immunocompetent Patient: A Case Report and Mini-Review. Case Reports in Hematology, 2017, 2017, 1-5.	0.3	8
231	Gambogenic acid synergistically potentiates bortezomib-induced apoptosis in multiple myeloma. Journal of Cancer, 2017, 8, 839-851.	1.2	23
232	Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis. Journal of Cancer, 2017, 8, 1801-1808.	1.2	5
233	Bortezomib resistance in multiple myeloma is associated with increased serine synthesis. Cancer & Metabolism, 2017, 5, 7.	2.4	115
234	Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab. Cancer Management and Research, 2017, Volume 9, 307-314.	0.9	25
235	Proteasome 20S in multiple myeloma: comparison of concentration and chymotrypsin-like activity in plasma and serum. Scandinavian Journal of Clinical and Laboratory Investigation, 2018, 78, 253-257.	0.6	2
236	Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide. Investigational New Drugs, 2018, 36, 797-809.	1.2	6
237	Molecular modeling on porphyrin derivatives as Î²5 subunit inhibitor of 20S proteasome. Computational Biology and Chemistry, 2018, 74, 230-238.	1.1	2
238	The start of a new wave: Developments in proteasome inhibition in multiple myeloma. European Journal of Haematology, 2018, 101, 220-236.	1.1	15
239	Panobinostat and Multiple Myeloma in 2018. Oncologist, 2018, 23, 516-517.	1.9	51
240	PD-1 /PD-L1 checkpoint in hematological malignancies. Leukemia Research, 2018, 67, 45-55.	0.4	33
241	Burkholderia multivorans: A rare yet emerging cause of bacterial meningitis. IDCases, 2018, 11, 61-63.	0.4	7

#	Article	IF	Citations
242	Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma. Cardio-Oncology, 2018, 4, 2.	0.8	3
243	Natural scaffolds in anticancer therapy and precision medicine. Biotechnology Advances, 2018, 36, 1563-1585.	6.0	35
244	Frail Patients with Newly Diagnosed Multiple Myeloma. , 2018, , 539-549.		1
245	The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphoma. Cancer Immunology, Immunotherapy, 2018, 67, 935-947.	2.0	21
246	Bavachin induces the apoptosis of multiple myeloma cell lines by inhibiting the activation of nuclear factor kappa B and signal transducer and activator of transcription 3. Biomedicine and Pharmacotherapy, 2018, 100, 486-494.	2.5	28
247	Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 311-320.	0.2	35
248	Indomethacin elicits proteasomal dysfunctions develops apoptosis through mitochondrial abnormalities. Journal of Cellular Physiology, 2018, 233, 1685-1699.	2.0	11
250	New and emerging therapies for acute and chronic graftversushost disease. Therapeutic Advances in Hematology, 2018, 9, 21-46.	1.1	90
251	Positioning of proteasome inhibitors in therapy of solid malignancies. Cancer Chemotherapy and Pharmacology, 2018, 81, 227-243.	1.1	113
252	Treatment of Patients in First or Second Relapse. , 2018, , 77-102.		0
253	Bortezomib for Neuromyelitis Optica Spectrum Disorder. JAMA Neurology, 2018, 75, 129.	4.5	1
254	Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study. European Journal of Haematology, 2018, 100, 10-19.	1.1	7
255	The Influence of Metabolism on Drug Response in Cancer. Frontiers in Oncology, 2018, 8, 500.	1.3	182
256	Ixazomib for the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy, 2018, 19, 1949-1968.	0.9	42
257	Ubiquitin Receptor RPN13 Mediates the Inhibitory Interaction of Diphenyldihaloketones CLEFMA and EF24 With the 26S Proteasome. Frontiers in Chemistry, 2018, 6, 392.	1.8	5
258	Pharmacophore-based virtual screening for identifying Î²5 subunit inhibitor of 20S proteasome. Computational Biology and Chemistry, 2018, 77, 64-71.	1.1	6
259	Proteasome-mediated protein degradation is enhanced by fusion ubiquitin with unstructured degron. Biochemical and Biophysical Research Communications, 2018, 501, 948-954.	1.0	2
260	Profilin 1 induces drug resistance through Beclin1 complexâ€mediated autophagy in multiple myeloma. Cancer Science, 2018, 109, 2706-2716.	1.7	31

#	Article	IF	Citations
261	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer Journal, 2018, 8, 70.	2.8	18
262	1,2,3,4,6-Penta-O-Galloyl-Beta-D-Glucopyranoside Inhibits Proliferation of Multiple Myeloma Cells Accompanied with Suppression of MYC Expression. Frontiers in Pharmacology, 2018, 9, 65.	1.6	14
263	Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model of Multiple Myeloma. Frontiers in Pharmacology, 2018, 9, 365.	1.6	58
264	Cardiovascular adverse events in modern myeloma therapy â€" Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica, 2018, 103, 1422-1432.	1.7	70
265	Oncolytic Viruses for Multiple Myeloma Therapy. Cancers, 2018, 10, 198.	1.7	20
266	A Complex Scenario and Underestimated Challenge: The Tumor Microenvironment, ER Stress, and Cancer Treatment. Current Medicinal Chemistry, 2018, 25, 2465-2502.	1.2	20
267	Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma. Journal of Hematology and Oncology, 2018, 11, 29.	6.9	36
268	Defining the Determinants of Specificity of Plasmodium Proteasome Inhibitors. Journal of the American Chemical Society, 2018, 140, 11424-11437.	6.6	54
269	Induction of apoptosis via proteasome inhibition in leukemia/lymphoma cells by two potent piperidones. Cellular Oncology (Dordrecht), 2018, 41, 623-636.	2.1	22
270	Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib. Clinical Pharmacokinetics, 2019, 58, 157-168.	1.6	92
271	Cross Talk Networks of Mammalian Target of Rapamycin Signaling With the Ubiquitin Proteasome System and Their Clinical Implications in Multiple Myeloma. International Review of Cell and Molecular Biology, 2019, 343, 219-297.	1.6	16
272	Anti-Multiple Myeloma Potential of Secondary Metabolites from Hibiscus sabdariffa. Molecules, 2019, 24, 2500.	1.7	22
273	MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy. Medical Oncology, 2019, 36, 75.	1.2	4
274	Preparation and biological evaluation of soluble tetrapeptide epoxyketone proteasome inhibitors. Bioorganic and Medicinal Chemistry, 2019, 27, 4151-4162.	1.4	4
275	XPO1 is a critical player for bortezomib resistance in multiple myeloma: A quantitative proteomic approach. Journal of Proteomics, 2019, 209, 103504.	1.2	44
276	DUBs, Hypoxia, and Cancer. Trends in Cancer, 2019, 5, 632-653.	3.8	125
277	Loss of FBXO9 Enhances Proteasome Activity and Promotes Aggressiveness in Acute Myeloid Leukemia. Cancers, 2019, 11, 1717.	1.7	16
278	The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation. Oncogene, 2019, 38, 3216-3231.	2.6	33

#	Article	IF	Citations
279	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia, 2019, 33, 1736-1746.	3.3	45
280	Involvement of E3 Ligases and Deubiquitinases in the Control of HIF-Î± Subunit Abundance. Cells, 2019, 8, 598.	1.8	19
281	Identification of key candidate genes and pathways in multiple myeloma by integrated bioinformatics analysis. Journal of Cellular Physiology, 2019, 234, 23785-23797.	2.0	48
282	Synthesis and Biological Activity of Peptide Î±-Ketoamide Derivatives as Proteasome Inhibitors. ACS Medicinal Chemistry Letters, 2019, 10, 1086-1092.	1.3	16
283	An optical and nonâ€invasive method to detect the accumulation of ubiquitin chains. Cell Biology International, 2019, 43, 1393-1406.	1.4	1
284	Acute Renal Failure in Critically Ill Cancer Patients. , 2019, , 1-16.		0
285	Proteasome Inhibitors as Sensitizing Agents for Cancer Chemotherapy. , 2019, , 207-228.		1
286	Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia, 2019, 33, 2266-2275.	3.3	385
287	Renal Replacement Therapy in Critically Ill Cancer Patients. , 2019, , 1-12.		0
288	Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy. Molecular Cancer Research, 2019, 17, 2331-2340.	1.5	21
289	Proteostasis In The Endoplasmic Reticulum: Road to Cure. Cancers, 2019, 11, 1793.	1.7	21
290	Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. The Cochrane Library, 2020, 2020, .	1.5	21
291	Targeting Metalloenzymes for Therapeutic Intervention. Chemical Reviews, 2019, 119, 1323-1455.	23.0	181
292	Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors. Cell Chemical Biology, 2019, 26, 340-351.e3.	2.5	83
293	Non-peptidic natural products as ubiquitin-proteasome inhibitors. Tetrahedron, 2019, 75, 817-853.	1.0	6
294	Phase 2 study of allâ€oral ixazomib, cyclophosphamide and lowâ€dose dexamethasone for relapsed/refractory multiple myeloma. British Journal of Haematology, 2019, 184, 536-546.	1.2	16
295	Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis. Cancers, 2019, 11, 66.	1.7	73
296	Quantitative structure-activity relationship and molecular docking studies on human proteasome inhibitors for anticancer activity targeting NF-ÎºB signaling pathway. Journal of Biomolecular Structure and Dynamics, 2020, 38, 3621-3632.	2.0	3

#	Article	IF	Citations
297	Discovery of a Small Molecule Probe of Rpn-6, an Essential Subunit of the 26S Proteasome. ACS Chemical Biology, 2020, 15, 554-561.	1.6	11
298	Tunable Synthesis of Î±-Amino Boronic Esters from Available Aldehydes and Amines through Sequential One-Pot Dehydration and Copper-Catalyzed Borylacylation. Journal of Organic Chemistry, 2020, 85, 2716-2724.	1.7	16
299	Renal replacement therapies. , 2020, , 290-298.e3.		0
300	Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib. Clinical Cancer Research, 2020, 26, 5506-5519.	3.2	20
301	Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors. Oncogene, 2020, 39, 5888-5901.	2.6	6
302	Proteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer . Drug Design, Development and Therapy, 2020, Volume 14, 4327-4342.	2.0	16
303	Gene Networks Constructed Through Simulated Treatment Learning can Predict Proteasome Inhibitor Benefit in Multiple Myeloma. Clinical Cancer Research, 2020, 26, 5952-5961.	3.2	5
304	Charge transfer reaction mechanisms of epoxyketone and boronated peptides at glassy carbon and boron doped diamond electrodes. Journal of Electroanalytical Chemistry, 2020, 878, 114733.	1.9	4
305	Comparison of bortezomib-cyclophosphamide-dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients. Hematology Reports, 2020, 12, 8267.	0.3	1
306	Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity. Molecular Cancer Research, 2020, 18, 1453-1464.	1.5	19
307	SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma. Molecular Cancer Research, 2020, 18, 632-643.	1.5	12
308	Proteasome Inhibitors for the Treatment of Multiple Myeloma. Cancers, 2020, 12, 265.	1.7	109
309	Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients . Cancer Management and Research, 2020, Volume 12, 431-441.	0.9	4
310	Crosstalk between HSPA5 arginylation and sequential ubiquitination leads to AKT degradation through autophagy flux. Autophagy, 2021, 17, 961-979.	4.3	30
311	Resistance mechanisms to immune checkpointsÂblockade by monoclonal antibody drugs in cancer immunotherapy: FocusÂon myeloma. Journal of Cellular Physiology, 2021, 236, 791-805.	2.0	13
312	Lightâ€Controlled Cellâ€Cycle Arrest and Apoptosis. Angewandte Chemie - International Edition, 2021, 60, 1187-1196.	7.2	28
313	Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report. Blood, 2021, 137, 1050-1060.	0.6	10
314	Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance. British Journal of Cancer, 2021, 124, 770-776.	2.9	16

#	Article	IF	Citations
315	Lightâ€Controlled Cellâ€Cycle Arrest and Apoptosis. Angewandte Chemie, 2021, 133, 1207-1216.	1.6	1
317	Î±-Aminoboronates: recent advances in their preparation and synthetic applications. Chemical Society Reviews, 2021, 50, 12151-12188.	18.7	44
318	MicroRNA-1252-5p Associated with Extracellular Vesicles Enhances Bortezomib Sensitivity in Multiple Myeloma Cells by Targeting Heparanase. OncoTargets and Therapy, 2021, Volume 14, 455-467.	1.0	16
319	Prognostic and Predictive Factors in Newly Diagnosed Multiple Myeloma Patients with Early Mortality with Prediction Matrix and Three and Five-Year Overall Survival. , 0, , .		0
320	Activation of Serum/Glucocorticoid Regulated Kinase 1/Nuclear Factor-ÎºB Pathway Are Correlated with Low Sensitivity to Bortezomib and Ixazomib in Resistant Multiple Myeloma Cells. Biomedicines, 2021, 9, 33.	1.4	8
321	The role of carfilzomib in relapsed/refractory multiple myeloma. Therapeutic Advances in Hematology, 2021, 12, 204062072110196.	1.1	11
322	Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy. Journal of Cancer, 2021, 12, 6198-6208.	1.2	7
324	Old and new generation proteasome inhibitors in multiple myeloma. Panminerva Medica, 2021, 62, 193-206.	0.2	6
325	The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma. Cancers, 2021, 13, 843.	1.7	12
326	Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study. EBioMedicine, 2021, 65, 103242.	2.7	10
327	Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	18
328	Deubiquitinating enzyme inhibitor alleviates cyclin A1â€mediated proteasome inhibitor tolerance in mixedâ€lineage leukemia. Cancer Science, 2021, 112, 2287-2298.	1.7	3
329	Ixazomib inhibits myeloma cell proliferation by targeting UBE2K. Biochemical and Biophysical Research Communications, 2021, 549, 1-7.	1.0	8
330	Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). Bone Marrow Transplantation, 2021, 56, 2533-2543.	1.3	7
331	Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model. International Journal of Molecular Sciences, 2021, 22, 5570.	1.8	4
332	Bioactive Compounds from Herbal Medicine Targeting Multiple Myeloma. Applied Sciences (Switzerland), 2021, 11, 4451.	1.3	1
333	Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma. Cancer Research, 2021, 81, 4581-4593.	0.4	8
334	Real-world evidence for carfilzomib dosing intensity on overall survival and treatment progression in multiple myeloma patients. Journal of Oncology Pharmacy Practice, 2022, 28, 1130-1139.	0.5	4

#	Article	IF	Citations
335	Mechanisms and Potential Treatment Options of Heart Failure in Patients With Multiple Myeloma. Cureus, 2021, 13, e15943.	0.2	2
336	Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome. Clinical Case Reports (discontinued), 2021, 9, e04287.	0.2	2
337	The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e510-e520.	0.2	12
338	Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma. Cancers, 2021, 13, 4019.	1.7	9
339	Teclistamab, a B-cell maturation antigenâ€ˆÃ—â€ˆCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet, The, 2021, 398, 665-674.	6.3	138
340	An update of new small-molecule anticancer drugs approved from 2015 to 2020. European Journal of Medicinal Chemistry, 2021, 220, 113473.	2.6	27
341	Proteasome inhibitors suppress MYB oncogenic activity in a p300-dependent manner. Cancer Letters, 2021, 520, 132-142.	3.2	15
344	Preclinical Studies on the Molecular Basis of Bortezomib Resistance and Modalities to Overcome Resistance in Hematological Malignancies. Resistance To Targeted Anti-cancer Therapeutics, 2014, , 181-204.	0.1	1
345	Exosomes mediate intercellular transfer of nonâ€“autonomous tolerance to proteasome inhibitors in mixedâ€lineage leukemia. Cancer Science, 2020, 111, 1279-1290.	1.7	28
346	Carfilzomib: A Next-Generation Proteasome Inhibitor for Multiple Myeloma Treatment. Clinical Journal of Oncology Nursing, 2013, 17, E35-E44.	0.3	3
347	The Dynamics of Connexin Expression, Degradation and Localisation Are Regulated by Gonadotropins during the Early Stages of In Vitro Maturation of Swine Oocytes. PLoS ONE, 2013, 8, e68456.	1.1	31
348	Bortezomib Resistance Can Be Reversed by Induced Expression of Plasma Cell Maturation Markers in a Mouse In Vitro Model of Multiple Myeloma. PLoS ONE, 2013, 8, e77608.	1.1	17
349	Inhibition of the MDM2 E3 Ligase Induces Apoptosis and Autophagy in Wild-Type and Mutant p53 Models of Multiple Myeloma, and Acts Synergistically with ABT-737. PLoS ONE, 2014, 9, e103015.	1.1	26
350	Inhibition of apoptosis may lead to the development of bortezomib resistance in multiple myeloma cancer cells. Turkish Journal of Biochemistry, 2021, 46, 65-71.	0.3	3
351	Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation. Oncotarget, 2016, 7, 59727-59741.	0.8	33
352	Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells. Oncotarget, 2016, 7, 70845-70856.	0.8	29
353	CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma. Oncotarget, 2016, 7, 78605-78618.	0.8	6
354	Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer. Oncotarget, 2014, 5, 7065-7080.	0.8	27

#	Article	IF	Citations
355	Novel proteasome inhibitor delanzomib sensitizes cervical cancer cells to doxorubicin-induced apoptosis via stabilizing tumor suppressor proteins in the p53 pathway. Oncotarget, 2017, 8, 114123-114135.	0.8	17
356	Î±-Radioimmunotherapy with 213Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma. Oncotarget, 2015, 6, 4692-4703.	0.8	42
357	KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models. Oncotarget, 2015, 6, 14814-14831.	0.8	67
358	Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System. Current Cancer Drug Targets, 2014, 14, 517-536.	0.8	224
359	Bortezomib â€" First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature. Recent Patents on Anti-Cancer Drug Discovery, 2020, 15, 113-131.	0.8	12
360	Therapeutic status and the prospect of CRISPR/Cas9 gene editing in multiple myeloma. Future Oncology, 2020, 16, 1125-1136.	1.1	3
361	Downregulation of DCC sensitizes multiple myeloma cells to bortezomib treatment. Molecular Medicine Reports, 2019, 19, 5023-5029.	1.1	2
362	In vitro comparison of the cytotoxic effects of statins on U266 myeloma cell line. Indian Journal of Medical Research, 2019, 150, 630.	0.4	6
363	Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses. Journal of the Advanced Practitioner in Oncology, 2015, 6, 308-18.	0.2	6
364	Nostocyclopeptides as New Inhibitors of 20S Proteasome. Biomolecules, 2021, 11, 1483.	1.8	2
365	High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors. Cells, 2021, 10, 2853.	1.8	2
366	Proteasome Inhibition and Hematopoietic Stem Cell Transplantation in Multiple Myeloma. , 0, , .		0
369	Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents. Journal of the Advanced Practitioner in Oncology, 2013, 4, .	0.2	7
370	Transitioning to an All Oral Therapy for Multiple Myeloma with the Novel Proteasome Inhibitor Ixazomib. , 2015, 12, .		0
371	AIDS-Related Plasmablastic Lymphoma. , 2016, , 73-81.		0
372	Adherence, Persistence, and Treatment Fatigue in Multiple Myeloma. Journal of the Advanced Practitioner in Oncology, 2016, 7, .	0.2	2
373	Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma. Journal of the Advanced Practitioner in Oncology, 2017, 8, .	0.2	0
376	Renal Replacement Therapy in Critically Ill Cancer Patients. , 2020, , 937-948.		0

#	Article	IF	Citations
378	Acute Renal Failure in Critically Ill Cancer Patients. , 2020, , 921-936.		0
379	Novel agents for the treatment of multiple myeloma: proteasome inhibitors and immunomodulatory agents. Journal of the Advanced Practitioner in Oncology, 2013, 4, 307-21.	0.2	9
382	Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma. Journal of the Advanced Practitioner in Oncology, 2017, 8, 401-405.	0.2	0
383	Bone marrow PD-1 positive T cells reflect tumor mass and prognosis in multiple myeloma. International Journal of Clinical and Experimental Pathology, 2018, 11, 304-313.	0.5	7
385	Using thrombocytopenia modeling to investigate the mechanisms underlying platelet depletion induced by panâ€proteasome inhibitors. CPT: Pharmacometrics and Systems Pharmacology, 2021, , .	1.3	3
386	MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner. Leukemia Research, 2022, 114, 106785.	0.4	6
387	Cancerâ€Cellâ€Biomimetic Nanoparticles for Targeted Therapy of Multiple Myeloma Based on Bone Marrow Homing. Advanced Materials, 2022, 34, e2107883.	11.1	38
388	Induction of m6A methylation in adipocyte exosomal LncRNAs mediates myeloma drug resistance. Journal of Experimental and Clinical Cancer Research, 2022, 41, 4.	3.5	52
389	poly(I:C) synergizes with proteasome inhibitors to induce apoptosis in cervical cancer cells. Translational Oncology, 2022, 18, 101362.	1.7	1
390	Microbial proteasomes as drug targets. PLoS Pathogens, 2021, 17, e1010058.	2.1	14
391	Neurological complications of multiple myeloma. , 2022, , 415-431.		0
392	secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics. Blood Cancer Journal, 2022, 12, 39.	2.8	5
393	Target Fishing Reveals a Novel Mechanism of 1,2,4-Oxadiazole Derivatives Targeting Rpn6, a Subunit of 26S Proteasome. Journal of Medicinal Chemistry, 2022, 65, 5029-5043.	2.9	7
394	Production of Epoxyketone Peptide-Based Proteasome Inhibitors by Streptomyces sp. BRA-346: Regulation and Biosynthesis. Frontiers in Microbiology, 2022, 13, 786008.	1.5	0
395	3D bioprinted, vascularized neuroblastoma tumor environment in fluidic chip devices for precision medicine drug testing. Biofabrication, 2022, 14, 035002.	3.7	28
396	Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network metaâ€analysis of randomized clinical trials. Hematological Oncology, 2022, 40, 233-242.	0.8	22
397	Carfilzomib Treatment Causes Molecular and Functional Alterations of Human Induced Pluripotent Stem Cellâ€"Derived Cardiomyocytes. Journal of the American Heart Association, 2021, 10, e022247.	1.6	15
398	A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen. Experimental Hematology, 2022, 111, 79-86.	0.2	2

#	Article	IF	Citations
403	Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retroâ€prospective observational study. European Journal of Haematology, 2022, 109, 373-380.	1.1	6
404	Multiple myeloma metabolism â€“ a treasure trove of therapeutic targets?. Frontiers in Immunology, 0, 13, .	2.2	8
405	The â€œYin and Yangâ€•of Unfolded Protein Response in Cancer and Immunogenic Cell Death. Cells, 2022, 11, 2899.	1.8	3
406	Therapeutic peptidomimetics for cancer treatment. , 2022, , 473-505.		0
407	Structural Aspects of Organic Compounds as Proteasome Inhibitors Addressed to Several Diseases. Engineering Materials, 2022, , 545-567.	0.3	0
408	The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?. Therapeutic Advances in Hematology, 2022, 13, 204062072211128.	1.1	4
410	Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe. Cancers, 2022, 14, 5311.	1.7	6
411	Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59. Cells, 2022, 11, 3365.	1.8	4
412	Rebooting the Myeloma Treatment Programme. European Medical Journal Hematology, 0, , 36-43.	0.0	0
413	Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data. Clinical Lymphoma, Myeloma and Leukemia, 2023, 23, 145-153.	0.2	1
415	Subcutaneous injection of a bortezomib-loaded thermosensitive hydrogel for the treatment of multiple myeloma. Chemical Engineering Journal, 2023, 455, 140600.	6.6	3
416	HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs. PLoS ONE, 2022, 17, e0274704.	1.1	2
418	Carfilzomib-Induced Tumor Lysis Syndrome and Biventricular Heart Failure in a Patient With Multiple Myeloma. Cureus, 2023, , .	0.2	0
419	Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study. Cancer Biology and Medicine, 2023, 20, 77-87.	1.4	1
420	Patterns of the Expression of Cyclin Genes in Bortezomib-Sensitive and Resistant Cells of Multiple Myeloma. Biology Bulletin, 2022, 49, S37-S45.	0.1	0
421	Dynamic single-cell RNA-seq analysis reveals distinct tumor program associated with microenvironmental remodeling and drug sensitivity in multiple myeloma. Cell and Bioscience, 2023, 13, .	2.1	4
422	Comprehensive Structureâ€“Activity Relationship Studies of Cepafungin Enabled by Biocatalytic Câ€“H Oxidations. ACS Central Science, 2023, 9, 239-251.	5.3	8
423	Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma. Molecules, 2023, 28, 1438.	1.7	4

#	Article	IF	Citations
424	Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader. Oncogene, 2023, 42, 994-1009.	2.6	6
425	LINC00461 Knockdown Enhances the Effect of Ixazomib in Multiple Myeloma Cells. Current Cancer Drug Targets, 2023, 23, 643-652.	0.8	1
426	Evolution of Natural Product Scaffolds as Potential Proteasome Inhibitors in Developing Cancer Therapeutics. Metabolites, 2023, 13, 509.	1.3	4
427	Protein degradation-based cancer therapy. , 2023, , 637-679.		0
428	Treatment Strategies for Multiple Myeloma Treatment and the Role of High-Throughput Screening for Precision Cancer Therapy. Advances in Experimental Medicine and Biology, 2023, , .	0.8	0